IBDEI2LV ; ; 04-FEB-2020
;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
Q:'DIFQR(358.3) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
Q Q
;;^UTILITY(U,$J,358.3,41616,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,41616,1,3,0)
;;=3^Dysphasia following other cerebrovascular disease
;;^UTILITY(U,$J,358.3,41616,1,4,0)
;;=4^I69.821
;;^UTILITY(U,$J,358.3,41616,2)
;;=^5007523
;;^UTILITY(U,$J,358.3,41617,0)
;;=I69.221^^155^2061^25
;;^UTILITY(U,$J,358.3,41617,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,41617,1,3,0)
;;=3^Dysphasia following oth nontraumatic intracranial hemorrhage
;;^UTILITY(U,$J,358.3,41617,1,4,0)
;;=4^I69.221
;;^UTILITY(U,$J,358.3,41617,2)
;;=^5007460
;;^UTILITY(U,$J,358.3,41618,0)
;;=G11.1^^155^2061^27
;;^UTILITY(U,$J,358.3,41618,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,41618,1,3,0)
;;=3^Early-onset cerebellar ataxia
;;^UTILITY(U,$J,358.3,41618,1,4,0)
;;=4^G11.1
;;^UTILITY(U,$J,358.3,41618,2)
;;=^5003753
;;^UTILITY(U,$J,358.3,41619,0)
;;=I69.392^^155^2061^28
;;^UTILITY(U,$J,358.3,41619,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,41619,1,3,0)
;;=3^Facial weakness following cerebral infarction
;;^UTILITY(U,$J,358.3,41619,1,4,0)
;;=4^I69.392
;;^UTILITY(U,$J,358.3,41619,2)
;;=^5007517
;;^UTILITY(U,$J,358.3,41620,0)
;;=I69.192^^155^2061^29
;;^UTILITY(U,$J,358.3,41620,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,41620,1,3,0)
;;=3^Facial weakness following nontraumatic intcrbl hemorrhage
;;^UTILITY(U,$J,358.3,41620,1,4,0)
;;=4^I69.192
;;^UTILITY(U,$J,358.3,41620,2)
;;=^5007454
;;^UTILITY(U,$J,358.3,41621,0)
;;=I69.292^^155^2061^31
;;^UTILITY(U,$J,358.3,41621,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,41621,1,3,0)
;;=3^Facial weakness following oth nontraumatic intcrn hemorrhage
;;^UTILITY(U,$J,358.3,41621,1,4,0)
;;=4^I69.292
;;^UTILITY(U,$J,358.3,41621,2)
;;=^5007486
;;^UTILITY(U,$J,358.3,41622,0)
;;=I69.092^^155^2061^30
;;^UTILITY(U,$J,358.3,41622,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,41622,1,3,0)
;;=3^Facial weakness following ntrm subarachnoid hemorrhage
;;^UTILITY(U,$J,358.3,41622,1,4,0)
;;=4^I69.092
;;^UTILITY(U,$J,358.3,41622,2)
;;=^5007422
;;^UTILITY(U,$J,358.3,41623,0)
;;=I69.892^^155^2061^32
;;^UTILITY(U,$J,358.3,41623,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,41623,1,3,0)
;;=3^Facial weakness following other cerebrovascular disease
;;^UTILITY(U,$J,358.3,41623,1,4,0)
;;=4^I69.892
;;^UTILITY(U,$J,358.3,41623,2)
;;=^5007548
;;^UTILITY(U,$J,358.3,41624,0)
;;=I69.351^^155^2061^34
;;^UTILITY(U,$J,358.3,41624,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,41624,1,3,0)
;;=3^Hemiplga fol cerebral infrc aff right dominant side
;;^UTILITY(U,$J,358.3,41624,1,4,0)
;;=4^I69.351
;;^UTILITY(U,$J,358.3,41624,2)
;;=^5007504
;;^UTILITY(U,$J,358.3,41625,0)
;;=I69.352^^155^2061^33
;;^UTILITY(U,$J,358.3,41625,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,41625,1,3,0)
;;=3^Hemiplga fol cerebral infrc aff left dominant side
;;^UTILITY(U,$J,358.3,41625,1,4,0)
;;=4^I69.352
;;^UTILITY(U,$J,358.3,41625,2)
;;=^5007505
;;^UTILITY(U,$J,358.3,41626,0)
;;=I69.353^^155^2061^35
;;^UTILITY(U,$J,358.3,41626,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,41626,1,3,0)
;;=3^Hemiplga fol cerebral infrc aff right nondom side
;;^UTILITY(U,$J,358.3,41626,1,4,0)
;;=4^I69.353
;;^UTILITY(U,$J,358.3,41626,2)
;;=^5007506
;;^UTILITY(U,$J,358.3,41627,0)
;;=I69.354^^155^2061^36
;;^UTILITY(U,$J,358.3,41627,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,41627,1,3,0)
;;=3^Hemiplga fol cerebral infrc affecting left nondom side
--- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI2LV 3791 printed Dec 13, 2024@02:31:16 Page 2
IBDEI2LV ; ; 04-FEB-2020
+1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
+2 if 'DIFQR(358.3)
QUIT
FOR I=1:2
SET X=$TEXT(Q+I)
if X=""
QUIT
SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
SET X=$EXTRACT(X,4,999)
if $ASCII(Y)=126
SET I=I+1
SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)
if $ASCII(Y)=61
SET Y=$EXTRACT(Y,2,999)
XECUTE NO
IF '$TEST
SET @X=Y
Q QUIT
+1 ;;^UTILITY(U,$J,358.3,41616,1,0)
+2 ;;=^358.31IA^4^2
+3 ;;^UTILITY(U,$J,358.3,41616,1,3,0)
+4 ;;=3^Dysphasia following other cerebrovascular disease
+5 ;;^UTILITY(U,$J,358.3,41616,1,4,0)
+6 ;;=4^I69.821
+7 ;;^UTILITY(U,$J,358.3,41616,2)
+8 ;;=^5007523
+9 ;;^UTILITY(U,$J,358.3,41617,0)
+10 ;;=I69.221^^155^2061^25
+11 ;;^UTILITY(U,$J,358.3,41617,1,0)
+12 ;;=^358.31IA^4^2
+13 ;;^UTILITY(U,$J,358.3,41617,1,3,0)
+14 ;;=3^Dysphasia following oth nontraumatic intracranial hemorrhage
+15 ;;^UTILITY(U,$J,358.3,41617,1,4,0)
+16 ;;=4^I69.221
+17 ;;^UTILITY(U,$J,358.3,41617,2)
+18 ;;=^5007460
+19 ;;^UTILITY(U,$J,358.3,41618,0)
+20 ;;=G11.1^^155^2061^27
+21 ;;^UTILITY(U,$J,358.3,41618,1,0)
+22 ;;=^358.31IA^4^2
+23 ;;^UTILITY(U,$J,358.3,41618,1,3,0)
+24 ;;=3^Early-onset cerebellar ataxia
+25 ;;^UTILITY(U,$J,358.3,41618,1,4,0)
+26 ;;=4^G11.1
+27 ;;^UTILITY(U,$J,358.3,41618,2)
+28 ;;=^5003753
+29 ;;^UTILITY(U,$J,358.3,41619,0)
+30 ;;=I69.392^^155^2061^28
+31 ;;^UTILITY(U,$J,358.3,41619,1,0)
+32 ;;=^358.31IA^4^2
+33 ;;^UTILITY(U,$J,358.3,41619,1,3,0)
+34 ;;=3^Facial weakness following cerebral infarction
+35 ;;^UTILITY(U,$J,358.3,41619,1,4,0)
+36 ;;=4^I69.392
+37 ;;^UTILITY(U,$J,358.3,41619,2)
+38 ;;=^5007517
+39 ;;^UTILITY(U,$J,358.3,41620,0)
+40 ;;=I69.192^^155^2061^29
+41 ;;^UTILITY(U,$J,358.3,41620,1,0)
+42 ;;=^358.31IA^4^2
+43 ;;^UTILITY(U,$J,358.3,41620,1,3,0)
+44 ;;=3^Facial weakness following nontraumatic intcrbl hemorrhage
+45 ;;^UTILITY(U,$J,358.3,41620,1,4,0)
+46 ;;=4^I69.192
+47 ;;^UTILITY(U,$J,358.3,41620,2)
+48 ;;=^5007454
+49 ;;^UTILITY(U,$J,358.3,41621,0)
+50 ;;=I69.292^^155^2061^31
+51 ;;^UTILITY(U,$J,358.3,41621,1,0)
+52 ;;=^358.31IA^4^2
+53 ;;^UTILITY(U,$J,358.3,41621,1,3,0)
+54 ;;=3^Facial weakness following oth nontraumatic intcrn hemorrhage
+55 ;;^UTILITY(U,$J,358.3,41621,1,4,0)
+56 ;;=4^I69.292
+57 ;;^UTILITY(U,$J,358.3,41621,2)
+58 ;;=^5007486
+59 ;;^UTILITY(U,$J,358.3,41622,0)
+60 ;;=I69.092^^155^2061^30
+61 ;;^UTILITY(U,$J,358.3,41622,1,0)
+62 ;;=^358.31IA^4^2
+63 ;;^UTILITY(U,$J,358.3,41622,1,3,0)
+64 ;;=3^Facial weakness following ntrm subarachnoid hemorrhage
+65 ;;^UTILITY(U,$J,358.3,41622,1,4,0)
+66 ;;=4^I69.092
+67 ;;^UTILITY(U,$J,358.3,41622,2)
+68 ;;=^5007422
+69 ;;^UTILITY(U,$J,358.3,41623,0)
+70 ;;=I69.892^^155^2061^32
+71 ;;^UTILITY(U,$J,358.3,41623,1,0)
+72 ;;=^358.31IA^4^2
+73 ;;^UTILITY(U,$J,358.3,41623,1,3,0)
+74 ;;=3^Facial weakness following other cerebrovascular disease
+75 ;;^UTILITY(U,$J,358.3,41623,1,4,0)
+76 ;;=4^I69.892
+77 ;;^UTILITY(U,$J,358.3,41623,2)
+78 ;;=^5007548
+79 ;;^UTILITY(U,$J,358.3,41624,0)
+80 ;;=I69.351^^155^2061^34
+81 ;;^UTILITY(U,$J,358.3,41624,1,0)
+82 ;;=^358.31IA^4^2
+83 ;;^UTILITY(U,$J,358.3,41624,1,3,0)
+84 ;;=3^Hemiplga fol cerebral infrc aff right dominant side
+85 ;;^UTILITY(U,$J,358.3,41624,1,4,0)
+86 ;;=4^I69.351
+87 ;;^UTILITY(U,$J,358.3,41624,2)
+88 ;;=^5007504
+89 ;;^UTILITY(U,$J,358.3,41625,0)
+90 ;;=I69.352^^155^2061^33
+91 ;;^UTILITY(U,$J,358.3,41625,1,0)
+92 ;;=^358.31IA^4^2
+93 ;;^UTILITY(U,$J,358.3,41625,1,3,0)
+94 ;;=3^Hemiplga fol cerebral infrc aff left dominant side
+95 ;;^UTILITY(U,$J,358.3,41625,1,4,0)
+96 ;;=4^I69.352
+97 ;;^UTILITY(U,$J,358.3,41625,2)
+98 ;;=^5007505
+99 ;;^UTILITY(U,$J,358.3,41626,0)
+100 ;;=I69.353^^155^2061^35
+101 ;;^UTILITY(U,$J,358.3,41626,1,0)
+102 ;;=^358.31IA^4^2
+103 ;;^UTILITY(U,$J,358.3,41626,1,3,0)
+104 ;;=3^Hemiplga fol cerebral infrc aff right nondom side
+105 ;;^UTILITY(U,$J,358.3,41626,1,4,0)
+106 ;;=4^I69.353
+107 ;;^UTILITY(U,$J,358.3,41626,2)
+108 ;;=^5007506
+109 ;;^UTILITY(U,$J,358.3,41627,0)
+110 ;;=I69.354^^155^2061^36
+111 ;;^UTILITY(U,$J,358.3,41627,1,0)
+112 ;;=^358.31IA^4^2
+113 ;;^UTILITY(U,$J,358.3,41627,1,3,0)
+114 ;;=3^Hemiplga fol cerebral infrc affecting left nondom side
